Jacob Johnson
Stock Analyst at Stephens & Co.
(2.91)
# 1,394
Out of 5,182 analysts
78
Total ratings
45.76%
Success rate
8.57%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $219.97 | +9.11% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $6.85 | -12.41% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $4.07 | +47.42% | 5 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $22.59 | +165.60% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $192.12 | +63.96% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $488.19 | +39.29% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $116.95 | +45.36% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $3.12 | +60.26% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $0.71 | +1,440.40% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $13.79 | +175.56% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $9.22 | +84.38% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $1.85 | +35.14% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $53.80 | +61.71% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $256.85 | +51.84% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $8.02 | +124.44% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.89 | +217.46% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $19.27 | +50.49% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $203.61 | -36.15% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $168.22 | +124.11% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $219.97
Upside: +9.11%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $6.85
Upside: -12.41%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $4.07
Upside: +47.42%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $22.59
Upside: +165.60%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $192.12
Upside: +63.96%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $488.19
Upside: +39.29%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $116.95
Upside: +45.36%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $3.12
Upside: +60.26%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $0.71
Upside: +1,440.40%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $13.79
Upside: +175.56%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $9.22
Upside: +84.38%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $1.85
Upside: +35.14%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $53.80
Upside: +61.71%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $256.85
Upside: +51.84%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $8.02
Upside: +124.44%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $1.89
Upside: +217.46%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $19.27
Upside: +50.49%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $203.61
Upside: -36.15%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $168.22
Upside: +124.11%